# Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)

> **NCT03666000** · PHASE1 · RECRUITING · sponsor: **Imugene Limited** · enrollment: 135 (estimated)

## Conditions studied

- Non-Hodgkin Lymphoma
- B-cell Acute Lymphoblastic Leukemia
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma

## Interventions

- **BIOLOGICAL:** Azer-cel
- **DRUG:** Fludarabine
- **DRUG:** Cyclophosphamide
- **DRUG:** IL-2

## Key facts

- **NCT ID:** NCT03666000
- **Lead sponsor:** Imugene Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2019-03-11
- **Primary completion:** 2027-06
- **Final completion:** 2027-06
- **Target enrollment:** 135 (ESTIMATED)
- **Last updated:** 2026-02-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03666000

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03666000, "Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT03666000. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*